Table 2.
Logistic regression model regressing switch status on patient characteristics, clinical features, and treatment history (final reduced model)
| Variable | OR | 95% CI | P value |
|---|---|---|---|
| Change in BSA involvement (ref: No change) | |||
| Decrease in BSA involvement | 0.69 | 0.55, 0.88 | 0.002 |
| Increase in BSA involvement | 6.23 | 5.17, 7.49 | < 0.001 |
| BSA category (ref: Mild [< 3%]) | |||
| Moderate (3–10%) | 4.19 | 3.40, 5.17 | < 0.001 |
| Severe (> 10%) | 5.94 | 4.19, 8.41 | < 0.001 |
| Patient global assessment | 1.01 | 1.00, 1.01 | < 0.001 |
| NBSM added | 4.87 | 2.92, 8.14 | < 0.001 |
| DLQI | 1.04 | 1.02, 1.06 | < 0.001 |
| Female | 1.29 | 1.12, 1.49 | < 0.001 |
| Age | 0.99 | 0.99, 1.00 | 0.001 |
| Psoriatic arthritis | 1.35 | 1.16, 1.56 | < 0.001 |
| Duration of biologic therapy at baseline (Ref: 5 to < 12 months) | |||
| 12 to < 24 months | 0.75 | 0.64, 0.88 | 0.001 |
| 24+ months | 0.79 | 0.66, 0.94 | 0.008 |
| Ethnicity (Hispanic) | 0.72 | 0.56, 0.92 | 0.008 |
| Number of prior topicals | 1.05 | 1.02, 1.09 | 0.002 |
| Year of baseline visit (ref: 2019) | |||
| 2020 | 0.73 | 0.59, 0.92 | 0.006 |
| 2021 | 0.73 | 0.58, 0.91 | 0.004 |
| 2022 | 0.72 | 0.58, 0.91 | 0.005 |
| Employment (full time) | 1.18 | 1.01, 1.38 | 0.041 |
| EQ-5D | 1.00 | 0.99, 1.00 | 0.140 |
| Fatigue | 1.00 | 1.00, 1.01 | 0.146 |
BSA body surface area, CI confidence interval, EQ-5D EuroQOL Five Dimensions Questionnaire, DLQI Dermatology Life Quality Index, NBSM non-biologic systemic medication, OR odds ratio, ref reference level